Key Stats for United Therapeutics Stock
- Price change for United Therapeutics stock Today: 12%
- $UTHR Stock Price as of Mar. 30: $588
- 52-Week High: $608
- $UTHR Stock Price Target: $611
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
United Therapeutics (UTHR) stock surged 12% on Monday after the company announced that its TETON-1 study of Tyvaso successfully treated idiopathic pulmonary fibrosis, a serious and progressive lung disease with limited treatment options.
The results were strong.
- Tyvaso increased forced vital capacity by 130.1 mL compared with placebo, a key measure of lung function.
- It also reduced the risk of clinical worsening in patients with IPF.
- Importantly, these results were even better than those observed in the company’s earlier TETON-2 study, which had already set a high bar.
When the two studies were combined, the integrated analysis showed a statistically significant improvement of 111.8 mL over placebo at week 52.
The drug worked consistently across different patient groups, including those already on background therapies like nintedanib or pirfenidone.
No new safety concerns were identified.
United Therapeutics plans to file for FDA priority review by the end of this summer to add IPF as an approved indication for Tyvaso.
Both the FDA and the European Medicines Agency have already granted orphan drug designation for the treatment.
This is a meaningful commercial opportunity.
On the company’s most recent earnings call,
- CEO Martine Rothblatt described three major product launches planned for 2027, with an IPF approval among them.
- She called it “better than anything the FDA has ever approved for IPF.”
- The company also surpassed $3 billion in total revenue for the first time in 2025, with double-digit growth driven by Tyvaso and Orenitram.
United Therapeutics stock has now hit a new 52-week high on the news, reflecting how significant this trial readout is for the company’s growth story.
See analysts’ growth forecasts and price targets for United Therapeutics stock (It’s free) >>>
What the Market Is Telling Us About United Therapeutics Stock
United Therapeutics stock doesn’t move 13% on noise.
This is a genuine catalyst.
A successful IPF label expansion would open a large new patient population for Tyvaso and add a third major growth driver alongside the existing pulmonary hypertension franchise.
Full TETON-1 data will be presented at the American Thoracic Society Annual Meeting in Orlando in May 2026, which could keep the stock in focus over the coming months.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does United Therapeutics Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
